MTOR and hepatocellular carcinoma: To further validate the results, nitazoxanide’s impact on the eight anti-HCC core targets (SRC, EGFR, CASP3, MMP9, mTOR, HIF1A, ERBB2, and PPARG) was investigated in silico.